RNA Therapeutics Market Growth is Attributed to Growing Prevalence of Chronic Diseases

The global RNA therapeutics market is growing under the influence of driving forces such as high prevalence of chronic diseases resulting in heightened demand for personalized medicine, technological advancements in RNA technology and therapy development, and augmented research funding to facilitate the development of cost-effective and reliable RNA therapies including vaccines and drugs. Furthermore, the government’s support for genetic studies and related products to address the growing disease burden accelerates the market expansion.

According to Markets and Data Research report, “RNA Therapeutics Market Assessment, By Region, Opportunities and Forecast, 2017-2031F”, global RNA therapeutics market was valued at USD 23,067.85 million in 2023 and is expected to register a CAGR of 11.25% during the forecast period. Several crucial factors influence the growth of the RNA therapeutics market. Continuous advancements in RNA technology for commercial expansion and the accuracy and effectiveness of treatment approaches are enhanced by improvements in messenger RNA (mRNA), small interfering RNA (siRNA), antisense oligonucleotides, and similar techniques, driving the market growth. These advancements address medication stability, target accuracy, and efficient administration strategies.

Funding for augmented RNA-based research is another essential driver of the market. Increased funding drives RNA-focused research, expediting innovation and converting findings into clinical implications in the RNA therapeutics market. Furthermore, the growing prevalence of chronic diseases creates a demand for personalized medicines like RNA therapies. RNA-based medications offer personalized solutions by utilizing unique genetic profiles to create specialized therapies that precisely address the unique needs of every patient.

The COVID-19 pandemic significantly boosted the demand for RNA therapeutics as vaccines like Comirnaty and Spikevax entered the market. Government support and industry cooperation among pharmaceutical companies continue to have a major impact. The global RNA therapeutics market is growing due to favorable regulatory settings, strategic alliances, and research, development, and commercialization-friendly conditions.

Download Free Sample Report

Spread through 340 pages, the "RNA Therapeutics Market" report includes an in-depth TOC, over 129 market data figures, latest market developments, key drivers and opportunities, and a thorough study of major company profiles. Moreover, the report offers strategic recommendations, pricing analysis, market share analysis, and value chain analysis in detail.

Key Takeaways:

• The growing prevalence of chronic diseases across the globe that leads to heightened demand for personalized medicine solutions, like RNA therapeutics, is anticipated to contribute to the market's growth.

 

• Increasing advancements in RNA technology for developing highly effective vaccines and drugs further lead to market expansion.

 

• The market for RNA-based therapeutics spiked during the COVID-19 pandemic and gave a kickstart to the opportunistic world of RNA-based therapies. The event proved the efficacy of RNA-based vaccines and led to the robust pipeline for variety of RNA vaccines to address different disease indications like oncology, infectious diseases, and others.

 

• In recent years, significant traction from investors and manufacturers flooding clinical pipeline products based on RNA therapeutics, and frequent mergers and acquisitions have been witnessed. The collaborative efforts of industry players and stakeholders further drive the market growth.

Global RNA therapeutics market is segmented in the following categories:

By Type: RNA Interference (RNAi) Therapeutics, mRNA Therapeutics, Antisense Oligonucleotide (ASO) Therapeutics, and Others

By Product: Vaccines and Drugs

By Indication: Rare Genetic Diseases/Hereditary Diseases, Infectious Diseases, and Others

By End-user: Hospitals, Academic Research Centers, Contract Research Organizations, and Others

By Region: North America, Europe, South America, Asia-Pacific, and Middle East and Africa

North America is currently leading RNA therapeutics market due to its high investment in research and development activities related to genetic and RNA-based therapies. The stronghold of key players in the region and their promising pipeline coupled with the high disposable income of residents of North American countries like the United States contributes to the largest market share of 43.83% in the region. Furthermore, the active involvement of the US FDA in the approval of drugs further enhances the market access for novel therapies to individuals. Rising awareness and government support in the form of reimbursement policies further support the market growth in the region.

Most of the marketed RNA therapies mainly address rare genetic diseases which cover a significant share of the rare genetic diseases segment in the market. Although all present RNA vaccines address infectious diseases (COVID-19) the pipeline products reflect a promising future for other indications as well. Due to widespread sales of COVID-19 vaccines based on RNA technology (Comirnaty and Spikevax), the share of the infectious diseases category is expected to be largest throughout the forecast period. Although with the changing prevalence of COVID-19 and its novel variants, the market may also expect uncertainties.

Major companies operating in global RNA therapeutics market include:

·         Pfizer Inc

·         Moderna, Inc

·         Biogen Inc.

·         Alnylam Pharmaceuticals, Inc

·         Sarepta Therapeutics, Inc

·         Novartis Pharmaceuticals Corporation

·         Ionis Pharmaceuticals, Inc

·         Jazz Pharmaceuticals Plc

·         NS Pharma, Inc.

·         Astellas Company (IVERIC bio, Inc.)

Market players in the global RNA therapeutics market are well-established companies. Pfizer and Moderna worked in collaboration with other firms to cater to the COVID-19 vaccine demand while all other players are involved in providing RNA-based drugs to address various disease indications. Several mergers and collaborations among key players have been reported in recent years, further enhancing manufacturing capabilities and pushing market growth.

In November 2023, Selecta Biosciences, Inc. merged with Cartesian Therapeutics, Inc. Cartesian Therapeutics is a clinical-stage biotechnology company, which specializes in RNA cell therapies for autoimmune diseases. The deal closed at USD 60.25 million. With the combined cash resources from both entities and the funds raised through private financing, the newly formed company is anticipated to have over USD 110 million available to bolster the development of Cartesian's pipeline, including advancing Descartes-08, a pioneering RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) for MG treatment, towards Phase 3 trials as well as other progressing RNA cell therapy programs.

“Global RNA Therapeutics Market Assessment, 2017-2031F”, evaluates the future growth potential of global RNA therapeutics market and provides statistics and information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision-makers to take investment decisions for their organizations more strategically. Moreover, the report identifies and examines the emerging trends along with key drivers, challenges, and opportunities in global RNA therapeutics market.

Contact
Mr. Vivek Gupta
5741 Cleveland street, 
Suite 120, VA beach, VA, USA 23462
Tel: +1 (757) 343-3258
Email: info@marketsandata.com
Website: https://www.marketsandata.com